Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has shared an update.
SynAct Pharma AB’s board has approved a share buyback program on Nasdaq Stockholm, using a mandate from a November 2025 extraordinary general meeting, to return excess liquidity to shareholders and optimize the company’s capital structure. The company plans to repurchase up to SEK 5 million of its own shares, capped at 10 percent of total outstanding shares, between 12 January and 28 February 2026, with all trades executed independently by Mangold Fondkommission under EU market abuse and safe harbour rules; the board intends to later seek shareholder approval to redeem the repurchased shares and restore share capital through a corresponding bonus issue, signaling confidence in the balance sheet while potentially enhancing value for existing investors.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on treating inflammatory diseases by selectively activating the melanocortin system. The company is developing a broad portfolio of oral and injectable melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving effects, helping patients restore immune balance and address chronic inflammation.
Average Trading Volume: 132,017
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.15B
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.